Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
New spin-out from TTP plc has developed 2nd generation Disc Pump tech., with applications in medical devices, healthcare, and scientific research.
The Biodesign Institute at Arizona State University plays an important role in addressing global healthcare challenges by developing bio-inspired solutions that can be translated into commercially viable products and clinical practices. With 11 different research centres, ranging from environmental biotechnology to infectious diseases and vaccinology, and evolutionary medicine and informatics to personalised diagnostics, the Institute is ideally positioned to capitalise on an extensive range of skills and capabilities to resolve complex issues affecting human health and the environment.
Quantitative real-time PCR (qPCR) has during the last two decades emerged as the preferred technology for nucleic acid analysis in routine as well as in research. qPCR has the sensitivity to detect a single molecule, the specificity to differentiate targets by a single nucleotide, and, because of its exponential nature, virtually unlimited dynamic range1.
The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or the discovery of drugs that control disease through the regulation of gene expression, mimicking the mechanism by which our bodies exert regulatory control over a range of normal and disease functions.
There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools to address many of the current problems that pharmaceutical companies must overcome. This in concert with the advent of personalised medicine and the demise of the therapeutic drug Blockbuster Model has necessitated a re-evaluation of the pharmaceutical business model.
The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and predictive tests and speculate on where this area is heading with regard to advanced technologies and likely future requirements.
Current escalating costs of drug discovery, development and drug launch continue to concern the pharmaceutical sector. This has been compounded by the advent of personalised medicine and its associated demands for individualised products as well as the demise of the blockbuster model.